搜尋結果
2021年7月10日 · 輝瑞-生物科技（Pfizer-BioNTech）疫苗——1.77億劑接種的疫苗當中出現145例心肌炎以及138 ... BBC News, 中文 BBC 值得信賴的原因 使用條款 隱私政策 Cookies ...
2021年3月3日 · Pfizer-BioNTech 據 FDA 稱，最常見的副作用為注射部位疼痛，其次為疲勞、頭痛、肌肉疼痛、發冷、關節疼痛和發燒。 在英國，兩名醫療保健工作者報告在接種疫苗後出現嚴重的過敏反應（過敏症）；阿拉斯加州的兩名醫療保健工作者報告在接種 Pfizer-BioNTech 疫苗後出現嚴重的過敏反應。
2020年11月18日 · This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program, and modRNA candidate BNT162b2
2022年8月23日 · today announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported interim vaccine efficacy data ...
2022年7月8日 · COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and other countries, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries.
1 中文 Melayu தம ழ VACCINATION INFORMATION SHEET PFIZER-BIONTECH / COMIRNATY COVID-19 VACCINE The Pfizer-BioNTech/Comirnaty vaccines have been authorised by the Health Sciences Authority (HSA) for use in Singapore. The vaccines
2022年6月3日 · World Health Organization. Français. This vaccine resource provides key vaccine-specific information for the Pfizer-BioNTech COVID-19 Vaccine Comirnaty®, a messenger RNA (mRNA) based vaccine against coronavirus disease (COVID-19). This document has been updated in English: version 03 June 2022.
